
## Supplementary Material




## Serum levels of complement markers of the acute phase in 10 naïve patients with neuromyelitis optica

spectrum disorders

Serum levels of sC5b-9, Ba, complement factor H (CFH), and complement factor I (CFI) in the acute phases of 10 patients that had not received any treatment at the time of the first-episode of neuromyelitis optica spectrum disorders, together with those of healthy controls, are shown by box plots.

\*\**p* < 0.01, and \*\*\**p* < 0.001, Student t-test.

## **Supplementary Figure 2.**



Changes of complement markers during the acute and remission phases of 10 naïve patients with neuromyelitis optica spectrum disorders

Changes of serum levels of sC5b-9, Ba, complement factor H (CFH) and complement factor I (CFI) during the acute and remission phases of 10 patients that had not received any treatment at the time of the first-episode of neuromyelitis optica spectrum disorders were analyzed. The dotted lines indicate changes in individual cases, and solid lines indicate changes in average levels. The gray shadow indicates reference ranges in Japanese healthy adults (sC5b-9: 181–1266 ng/ml, Ba: 438–1546 ng/ml, CFH: 238–663  $\mu$ g/ml, CFI: 11–42  $\mu$ g/ml) (15). \**p* < 0.01, paired t-test.

•		-
Acute phase	Remission	<i>p</i> -values
$7535\pm2320$	$7492\pm3819$	0.991
$5203\pm2089$	$4224 \pm 1582$	0.698
$1582\pm729$	$2561 \pm 1976$	0.420
$580\pm471$	$529\pm238$	0.873
$4.2\pm0.4$	$3.8 \pm 0.4$	0.865
$0.600\pm0.861$	$0.339\pm0.685$	0.538
$22.9\pm40.4$	$2.9\pm3.7$	0.246
$40.9 \pm 14.4$	$31.4 \pm 5.6$	0.654
10 (100%)	5 (50.0%)	
0 (0.0%)	3 (30.0%)	
0 (0.0%)	1 (10.0%)	
0 (0.0%)	1 (10.0%)	
0 (0.0%)	0 (0.0%)	
	$7535 \pm 2320$ $5203 \pm 2089$ $1582 \pm 729$ $580 \pm 471$ $4.2 \pm 0.4$ $0.600 \pm 0.861$ $22.9 \pm 40.4$ $40.9 \pm 14.4$ $10 (100\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$	$7535 \pm 2320$ $7492 \pm 3819$ $5203 \pm 2089$ $4224 \pm 1582$ $1582 \pm 729$ $2561 \pm 1976$ $580 \pm 471$ $529 \pm 238$ $4.2 \pm 0.4$ $3.8 \pm 0.4$ $0.600 \pm 0.861$ $0.339 \pm 0.685$ $22.9 \pm 40.4$ $2.9 \pm 3.7$ $40.9 \pm 14.4$ $31.4 \pm 5.6$ $10 (100\%)$ $5 (50.0\%)$ $0 (0.0\%)$ $1 (10.0\%)$ $0 (0.0\%)$ $1 (10.0\%)$

Supplementary Table 1. Laboratory Data and Treatments in NMOSD-naïve patients

Data are shown as mean  $\pm$  standard deviation. Abbreviations: CRP = C-reactive protein;

NMOSD = neuromyelitis optica spectrum disorders.

	sC5b-9	Ba	CFH	CFI	
Age	-0.175	-0.167	0.036	-0.008	
Disease duration	0.085	-0.026	-0.316	<u>0.520</u>	
EDSS	0.140	-0.032	-0.248	0.183	
White Blood Cells	0.125	0.004	0.042	0.176	
Neutrophils	0.033	0.019	-0.070	0.189	
Lymphocytes	0.033	-0.096	0.259	-0.013	
Monocytes	0.041	-0.024	0.177	0.014	
Albumin	0.154	0.059	-0.198	0.128	
CRP	-0.040	-0.001	0.399	-0.396	
CSF cell count	0.104	0.180	-0.074	-0.179	
CSF protein	-0.228	-0.249	-0.148	0.481	

Supplementary Table 2. Correlations between serum complement marker levels and clinical data in the acute phase of NMOSD

Data are shown as r value. Abbreviations: CSF=cerebrospinal fluid;

NMOSD=neuromyelitis optica spectrum disorders; EDSS = expanded disability status scale. Underline: significant correlation